Follicle Stimulating Hormone Market By Type (Recombinant FSH, Urinary FSH) , By Application (Infertility Treatment, Assisted Reproductive Technology) By End User (Hospitals, Fertility Clinics, Cryobanks) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Follicle Stimulating Hormone Market
The follicle stimulating hormone market was valued at $1.94 billion in 2023 and is estimated to reach $3.74 billion by 2035, exhibiting a CAGR of 5.7% from 2024 to 2035.
Follicle stimulating hormone (FSH) is a vital hormone produced by the pituitary gland that plays a key role in reproductive health. In females, FSH is specifically involved in the menstrual cycle and ovarian function as it stimulates the development of ovarian follicles containing the ovum. FSH further regulates the production of two essential hormones involved in menstrual cycle and pregnancy that are estrogen and progesterone. In males, the hormone stimulates sperm cells production in the testes. It works alongside luteinizing hormone (LH) to regulate fertility and normal reproductive functions. Along with its reproductive functions, FSH impacts the bone health and is essential in conditions such as polycystic ovary syndrome (PCOS) and infertility.
Increase in prevalence of infertility and rise in awareness among individuals regarding the benefits of FSH-based medications are the key factors driving the growth of the follicle stimulating hormone market. Moreover, increase in adoption of assisted reproductive technology (ART) is expected to significantly augment the growth of the market. Currently, the exploration of FSH in several regeneration-related functions of endometrial stem cells is acquiring traction. According to scientists, this is predicted to subsequently increase pregnancy rates among females.
However, fertility-related treatments, including FSH therapies, are not covered under insurance policies in several regions. This makes such treatments expensive for several individuals, thus preventing them from undergoing such treatments and restraining the market development. Moreover, the side-effects of FSH administration are severe in some cases, including multiple pregnancies, ovarian hyperstimulation syndrome (OHSS), and hormonal imbalances. This limits the utilization of FSF and presents challenges for the market players. On the contrary, infertility rates are surging globally owing to lifestyle changes and environmental stressors. As per a 2023 article by Center of Disease Control and Prevention, 13.4% of women between the age 15-49 were reported to suffer from impaired fecundity. These statistics indicate a promising future for the market.
Segment Overview
The follicle stimulating hormone market is segmented into type, application, end user, and region. On the basis of type, the market is bifurcated into recombinant FSH and urinary FSH. By application, it is classified into infertility treatment and assisted reproductive technology. As per end user, it is categorized into hospitals, fertility clinics, and cryobanks. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of type, the recombinant FSH segment dominated the market in 2023.
By application, the infertility treatment segment acquired a high market share in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The major players operating in the follicle stimulating hormone market are Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Merck Specialities Pvt Ltd., Intas Pharmaceuticals Ltd., and Cipla Ltd. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Key Market Segments
By Type
Recombinant FSH
Urinary FSH
By Application
Infertility Treatment
Assisted Reproductive Technology
By End User
Hospitals
Fertility Clinics
Cryobanks
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Pfizer Inc.
Novartis AG
Abbott Laboratories
Sanofi S.A.
Boehringer Ingelheim GmbH
Merck KGaA
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals Ltd.
Cipla Ltd.
Zydus Lifesciences Limited
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: FOLLICLE STIMULATING HORMONE MARKET, BY TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
- 4.2. Recombinant FSH
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Urinary FSH
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- CHAPTER 5: FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
- 5.2. Infertility Treatment
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Assisted Reproductive Technology
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: FOLLICLE STIMULATING HORMONE MARKET, BY END USER
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
- 6.2. Hospitals
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Fertility Clinics
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Cryobanks
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: FOLLICLE STIMULATING HORMONE MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Follicle Stimulating Hormone Market
- 7.2.6.1. Market Size and Forecast, By Type
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Follicle Stimulating Hormone Market
- 7.2.7.1. Market Size and Forecast, By Type
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Follicle Stimulating Hormone Market
- 7.2.8.1. Market Size and Forecast, By Type
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By End User
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Follicle Stimulating Hormone Market
- 7.3.6.1. Market Size and Forecast, By Type
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. France Follicle Stimulating Hormone Market
- 7.3.7.1. Market Size and Forecast, By Type
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. UK Follicle Stimulating Hormone Market
- 7.3.8.1. Market Size and Forecast, By Type
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Italy Follicle Stimulating Hormone Market
- 7.3.9.1. Market Size and Forecast, By Type
- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. Spain Follicle Stimulating Hormone Market
- 7.3.10.1. Market Size and Forecast, By Type
- 7.3.10.2. Market Size and Forecast, By Application
- 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest Of Europe Follicle Stimulating Hormone Market
- 7.3.11.1. Market Size and Forecast, By Type
- 7.3.11.2. Market Size and Forecast, By Application
- 7.3.11.3. Market Size and Forecast, By End User
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Follicle Stimulating Hormone Market
- 7.4.6.1. Market Size and Forecast, By Type
- 7.4.6.2. Market Size and Forecast, By Application
- 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. China Follicle Stimulating Hormone Market
- 7.4.7.1. Market Size and Forecast, By Type
- 7.4.7.2. Market Size and Forecast, By Application
- 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. Australia Follicle Stimulating Hormone Market
- 7.4.8.1. Market Size and Forecast, By Type
- 7.4.8.2. Market Size and Forecast, By Application
- 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. India Follicle Stimulating Hormone Market
- 7.4.9.1. Market Size and Forecast, By Type
- 7.4.9.2. Market Size and Forecast, By Application
- 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. South Korea Follicle Stimulating Hormone Market
- 7.4.10.1. Market Size and Forecast, By Type
- 7.4.10.2. Market Size and Forecast, By Application
- 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Follicle Stimulating Hormone Market
- 7.4.11.1. Market Size and Forecast, By Type
- 7.4.11.2. Market Size and Forecast, By Application
- 7.4.11.3. Market Size and Forecast, By End User
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Follicle Stimulating Hormone Market
- 7.5.6.1. Market Size and Forecast, By Type
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. Saudi Arabia Follicle Stimulating Hormone Market
- 7.5.7.1. Market Size and Forecast, By Type
- 7.5.7.2. Market Size and Forecast, By Application
- 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. South Africa Follicle Stimulating Hormone Market
- 7.5.8.1. Market Size and Forecast, By Type
- 7.5.8.2. Market Size and Forecast, By Application
- 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Follicle Stimulating Hormone Market
- 7.5.9.1. Market Size and Forecast, By Type
- 7.5.9.2. Market Size and Forecast, By Application
- 7.5.9.3. Market Size and Forecast, By End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Pfizer Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Novartis AG
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Abbott Laboratories
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Sanofi S.A.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Boehringer Ingelheim GmbH
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Merck KGaA
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Teva Pharmaceutical Industries Ltd.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Intas Pharmaceuticals Ltd.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Cipla Ltd.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Zydus Lifesciences Limited
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- TABLE 1. GLOBAL FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 2. FOLLICLE STIMULATING HORMONE MARKET FOR RECOMBINANT FSH, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 3. FOLLICLE STIMULATING HORMONE MARKET FOR URINARY FSH, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 4. GLOBAL FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 5. FOLLICLE STIMULATING HORMONE MARKET FOR INFERTILITY TREATMENT, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 6. FOLLICLE STIMULATING HORMONE MARKET FOR ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 7. GLOBAL FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 8. FOLLICLE STIMULATING HORMONE MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 9. FOLLICLE STIMULATING HORMONE MARKET FOR FERTILITY CLINICS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 10. FOLLICLE STIMULATING HORMONE MARKET FOR CRYOBANKS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 11. FOLLICLE STIMULATING HORMONE MARKET, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 12. NORTH AMERICA FOLLICLE STIMULATING HORMONE MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 13. NORTH AMERICA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 14. NORTH AMERICA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 15. NORTH AMERICA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 16. U.S. FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 17. U.S. FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 18. U.S. FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 19. CANADA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 20. CANADA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 21. CANADA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 22. MEXICO FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 23. MEXICO FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 24. MEXICO FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 25. EUROPE FOLLICLE STIMULATING HORMONE MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 26. EUROPE FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 27. EUROPE FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 28. EUROPE FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 29. GERMANY FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 30. GERMANY FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 31. GERMANY FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 32. FRANCE FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 33. FRANCE FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 34. FRANCE FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 35. UK FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 36. UK FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 37. UK FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 38. ITALY FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 39. ITALY FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 40. ITALY FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 41. SPAIN FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 42. SPAIN FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 43. SPAIN FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 44. REST OF EUROPE FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 45. REST OF EUROPE FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 46. REST OF EUROPE FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 47. ASIA-PACIFIC FOLLICLE STIMULATING HORMONE MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 48. ASIA-PACIFIC FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 49. ASIA-PACIFIC FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 50. ASIA-PACIFIC FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 51. JAPAN FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 52. JAPAN FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 53. JAPAN FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 54. CHINA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 55. CHINA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 56. CHINA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 57. AUSTRALIA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 58. AUSTRALIA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 59. AUSTRALIA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 60. INDIA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 61. INDIA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 62. INDIA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 63. SOUTH KOREA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 64. SOUTH KOREA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 65. SOUTH KOREA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 66. REST OF ASIA-PACIFIC FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 69. LAMEA FOLLICLE STIMULATING HORMONE MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 70. LAMEA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 71. LAMEA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 72. LAMEA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 73. BRAZIL FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 74. BRAZIL FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 75. BRAZIL FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 76. SAUDI ARABIA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 77. SAUDI ARABIA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 78. SAUDI ARABIA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 79. SOUTH AFRICA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 80. SOUTH AFRICA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 81. SOUTH AFRICA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 82. REST OF LAMEA FOLLICLE STIMULATING HORMONE MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 83. REST OF LAMEA FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 84. REST OF LAMEA FOLLICLE STIMULATING HORMONE MARKET, BY END USER, 2024 - 2033 ($MILLION)
- TABLE 85. PFIZER INC.: KEY EXECUTIVES
- TABLE 86. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 87. PFIZER INC.: OPERATING SEGMENTS
- TABLE 88. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 89. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 90. NOVARTIS AG: KEY EXECUTIVES
- TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 92. NOVARTIS AG: OPERATING SEGMENTS
- TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 94. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 95. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 96. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 97. ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 98. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 99. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 100. SANOFI S.A.: KEY EXECUTIVES
- TABLE 101. SANOFI S.A.: COMPANY SNAPSHOT
- TABLE 102. SANOFI S.A.: OPERATING SEGMENTS
- TABLE 103. SANOFI S.A.: PRODUCT PORTFOLIO
- TABLE 104. SANOFI S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 105. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
- TABLE 106. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
- TABLE 107. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
- TABLE 108. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
- TABLE 109. BOEHRINGER INGELHEIM GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 110. MERCK KGAA: KEY EXECUTIVES
- TABLE 111. MERCK KGAA: COMPANY SNAPSHOT
- TABLE 112. MERCK KGAA: OPERATING SEGMENTS
- TABLE 113. MERCK KGAA: PRODUCT PORTFOLIO
- TABLE 114. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 115. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 120. INTAS PHARMACEUTICALS LTD.: KEY EXECUTIVES
- TABLE 121. INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
- TABLE 122. INTAS PHARMACEUTICALS LTD.: OPERATING SEGMENTS
- TABLE 123. INTAS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
- TABLE 124. INTAS PHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 125. CIPLA LTD.: KEY EXECUTIVES
- TABLE 126. CIPLA LTD.: COMPANY SNAPSHOT
- TABLE 127. CIPLA LTD.: OPERATING SEGMENTS
- TABLE 128. CIPLA LTD.: PRODUCT PORTFOLIO
- TABLE 129. CIPLA LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 130. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
- TABLE 131. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
- TABLE 132. ZYDUS LIFESCIENCES LIMITED: OPERATING SEGMENTS
- TABLE 133. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
- TABLE 134. ZYDUS LIFESCIENCES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- FIGURE 1. GLOBAL FOLLICLE STIMULATING HORMONE MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF FOLLICLE STIMULATING HORMONE MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN FOLLICLE STIMULATING HORMONE MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALFOLLICLE STIMULATING HORMONE MARKET
- FIGURE 10. GLOBAL FOLLICLE STIMULATING HORMONE MARKET SEGMENTATION, BY TYPE
- FIGURE 11. FOLLICLE STIMULATING HORMONE MARKET FOR RECOMBINANT FSH, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 12. FOLLICLE STIMULATING HORMONE MARKET FOR URINARY FSH, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 13. GLOBAL FOLLICLE STIMULATING HORMONE MARKET SEGMENTATION, BY APPLICATION
- FIGURE 14. FOLLICLE STIMULATING HORMONE MARKET FOR INFERTILITY TREATMENT, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 15. FOLLICLE STIMULATING HORMONE MARKET FOR ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 16. GLOBAL FOLLICLE STIMULATING HORMONE MARKET SEGMENTATION, BY END USER
- FIGURE 17. FOLLICLE STIMULATING HORMONE MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 18. FOLLICLE STIMULATING HORMONE MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 19. FOLLICLE STIMULATING HORMONE MARKET FOR CRYOBANKS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 24. COMPETITIVE DASHBOARD
- FIGURE 25. COMPETITIVE HEATMAP: FOLLICLE STIMULATING HORMONE MARKET
- FIGURE 26. TOP PLAYER POSITIONING, 2023
- FIGURE 27. PFIZER INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 28. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 29. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 30. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
- FIGURE 31. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 32. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 33. ABBOTT LABORATORIES: NET SALES, 2021-2023 ($MILLION)
- FIGURE 34. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 35. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 36. SANOFI S.A.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 37. SANOFI S.A.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 38. SANOFI S.A.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 39. BOEHRINGER INGELHEIM GMBH: NET SALES, 2021-2023 ($MILLION)
- FIGURE 40. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 41. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 42. MERCK KGAA: NET SALES, 2021-2023 ($MILLION)
- FIGURE 43. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 44. MERCK KGAA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 45. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 46. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 47. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 48. INTAS PHARMACEUTICALS LTD.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 49. INTAS PHARMACEUTICALS LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 50. INTAS PHARMACEUTICALS LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 51. CIPLA LTD.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 52. CIPLA LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 53. CIPLA LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 54. ZYDUS LIFESCIENCES LIMITED: NET SALES, 2021-2023 ($MILLION)
- FIGURE 55. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 56. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook